Tasigna News and Research

RSS
Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Regulatory bias against taking oral anti-cancer medications with food places patients at risk of overdose

Regulatory bias against taking oral anti-cancer medications with food places patients at risk of overdose

Medco announces new offerings within Advanced Oncology Solutions

Medco announces new offerings within Advanced Oncology Solutions

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Rush University enrolls first U.S. patient in international clinical trial for melanoma

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

CAS researchers confirm Gleevec’s first generation drug targets chronic myelogenous leukemia

CAS researchers confirm Gleevec’s first generation drug targets chronic myelogenous leukemia

US oncology announces its contributions in development of 42 novel cancer therapies

US oncology announces its contributions in development of 42 novel cancer therapies

Tasigna receives approval for chronic myeloid leukemia in Canada

Tasigna receives approval for chronic myeloid leukemia in Canada

Asuragen, Life Technologies announce European launch of BCR/ABL1 Quant Test

Asuragen, Life Technologies announce European launch of BCR/ABL1 Quant Test

FDA approves new indication for Tasigna in treatment of rare blood cancer

FDA approves new indication for Tasigna in treatment of rare blood cancer

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

CytRx granted U.S. Patent for bafetinib

CytRx granted U.S. Patent for bafetinib

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

High OOP costs discouraging many cancer patients from filling prescriptions

High OOP costs discouraging many cancer patients from filling prescriptions

ChemGenex shares falter as FDA requests more data on new leukemia drug

ChemGenex shares falter as FDA requests more data on new leukemia drug

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML